Dmitriy Sonkin

Dmitriy Sonkin

UNVERIFIED PROFILE

Are you Dmitriy Sonkin?   Register this Author

Register author
Dmitriy Sonkin

Dmitriy Sonkin

Publications by authors named "Dmitriy Sonkin"

Are you Dmitriy Sonkin?   Register this Author

22Publications

534Reads

40Profile Views

Bioinformatics Tools and Resources for Cancer Immunotherapy Study.

Methods Mol Biol 2020 ;2055:649-678

Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-9773-2_29DOI Listing
January 2020

Detection of homozygous deletions in tumor-suppressor genes ranging from dozen to hundreds nucleotides in cancer models.

Hum Mutat 2017 11 23;38(11):1449-1453. Epub 2017 Aug 23.

National Cancer Institute, Division of Cancer Treatment and Diagnosis, Biometric Research Program, Computational and Systems Biology Branch, Rockville, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/humu.23308DOI Listing
November 2017

Small cell lung carcinoma cell line screen of etoposide/carboplatin plus a third agent.

Cancer Med 2017 Aug 1;6(8):1952-1964. Epub 2017 Aug 1.

Molecular Pharmacology Group, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, 21702.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.1131DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548882PMC
August 2017

Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression.

J Natl Cancer Inst 2016 10 31;108(10). Epub 2016 May 31.

Affiliations of authors: Molecular Pharmacology Group, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD (DE, TS, RD, JL, CO, RR, MS, JC, EH, NF, AM); Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis (MK, GK, JM, BAT), Biometric Research Program, Division of Cancer Treatment and Diagnosis (EP, DS), and Cancer Therapy Evaluation Program (SM), National Cancer Institute, Rockville, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw122DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279282PMC
October 2016

TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data.

Hum Mutat 2016 09 8;37(9):865-76. Epub 2016 Jul 8.

Group of Molecular Mechanisms and Biomarkers, International Agency for Research on Cancer, Lyon Cedex 08, 69372, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/humu.23035DOI Listing
September 2016

Integrative modeling of multi-omics data to identify cancer drivers and infer patient-specific gene activity.

BMC Syst Biol 2016 Feb 11;10:16. Epub 2016 Feb 11.

Duke University Medical Center, Durham, 27708, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12918-016-0260-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4750289PMC
February 2016

Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors.

Authors:
Dmitriy Sonkin

Elife 2015 Oct 22;4. Epub 2015 Oct 22.

Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7554/eLife.10279DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728122PMC
October 2015

Inhibiting Tankyrases sensitizes KRAS-mutant cancer cells to MEK inhibitors via FGFR2 feedback signaling.

Cancer Res 2014 Jun 18;74(12):3294-305. Epub 2014 Apr 18.

Authors' Affiliations: Oncology Department, Novartis Institutes for BioMedical Research; Zalicus Inc., Cambridge; and Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-14-0138-TDOI Listing
June 2014

Integrative radiogenomic profiling of squamous cell lung cancer.

Cancer Res 2013 Oct 26;73(20):6289-98. Epub 2013 Aug 26.

Authors' Affiliations: Harvard Radiation Oncology Program; Division of Medical Sciences, Harvard University; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School; Department of Medical Oncology, Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute; Department of Pathology, Brigham and Women's Hospital, Boston; Chemical Biology Program; Howard Hughes Medical Institute, The Broad Institute of MIT and Harvard; Novartis Institute for Biomedical Research; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts; and Department of Medicine, Baylor College of Medicine, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-1616DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3856255PMC
October 2013

Tumor suppressors status in cancer cell line Encyclopedia.

Mol Oncol 2013 Aug 11;7(4):791-8. Epub 2013 Apr 11.

University of South Wales, Pontypridd, Wales, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2013.04.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3729735PMC
August 2013

Genetic mechanisms in Apc-mediated mammary tumorigenesis.

PLoS Genet 2009 Feb 6;5(2):e1000367. Epub 2009 Feb 6.

Harvard-Partners Center for Genetics and Genomics, Harvard Medical School, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1371/journal.pgen.1000367DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2629572PMC
February 2009